@FierceMedDev: Staar got key FDA panel backing for its new ocular lens. Chances for approval now pretty high. More | Follow @FierceMedDev
@MarkHFierce: Boston Scientific gained a CE mark for new MRI-safe pacer leads. News | Follow @MarkHFierce
@MichaelGFierce: ICYMI: NeuroDerm preps for Parkinson's patch PhII trial. More from FierceDrugDelivery | Follow @MichaelGFierce
@EmilyWFierce: Following the 5-second rule for food is like playing Russian roulette with your gut, says one molecular biologist. Article | Follow @EmilyWFierce
> Boston Scientific ($BSX) won CE-mark approval and has begun its European marketing for new MRI-compatible pacing leads. Release
> California's BioCardia won a CE mark for a device designed to enable easier navigation through vasculature during the delivery of biotherapeutics and medical devices. Release
> Germany's eZono gained a 510(k) clearance for its new tablet ultrasound system with an added feature that provides needle guidance for various procedures. Item
> New York's Vasomedical said that a subsidiary won regulatory approval in China to begin marketing its new MobiCare wireless patient monitors there. Release
> PerkinElmer ($PKI) will help expand access to in vitro fertilization tests made by Good Start Genetics in a new collaboration deal. Release
Biotech News
@FierceBiotech: ICYMI over the weekend: Chimerix started the week as a punching bag, then pulls off a TKO. Editor's Corner | Follow @FierceBiotech
@JohnCFierce: Bristol-Myers inks a $350M deal to pair with FivePrime on immuno-oncology gold rush. Story | Follow @JohnCFierce
@DamianFierce: Amgen hits the mark in another of its 14 PhIII studies of the PCSK9-blocking evolocumab. Release | Follow @DamianFierce
@EmilyMFierce: NIH cuts, sequestration hampering cancer research. Story | Follow @EmilyMFierce
> Intercept scores a PhIII win for lead drug following Friday night frights. More
> Amgen's viral cancer vaccine T-Vec tackles melanoma tumors in PhIII. Article
Pharma News
@FiercePharma: Best-read weekend news: Gilead's hot-selling Sovaldi draws more patent attacks. Story | Follow @FiercePharma
@TracyStaton: Tops at FiercePharma Wed.: CA panel shivs Gilead's Sovaldi on price, suggests focusing it on sickest hep C patients. More | Follow @TracyStaton
@EricPFierce: New twist on KV vs FDA over Makena. FDA cites compounder. News | Follow @EricPFierce
@CarlyHFierce: Going to check out South America for a few days. Talk to you Thursday, Twitterverse! | Follow @CarlyHFierce
> Bristol-Myers' Eliquis gets new FDA nod for use after ortho surgery. Article
> In latest marketing-reform move, GSK recruits in-house doctors to speak for products. More
> Shire recalls Gaucher drug but says it has plenty of supply in reserve. News
> Italian prosecutors home in on Roche, Novartis execs in eye-drug collusion probe. Story
CRO News
> Charles River snaps up Galapagos' CRO biz for $179M. News
> Clinipace dives into Asia with Choice Pharma buyout. Story
> WuXi deepens its genomics might with Illumina, Pacific Biomarkers deals. Article
> Post-merger BioClinica looks to corner the imaging market. Piece
> PPD lands a federal bioterror deal worth up to $100M. News
> Meet DPx, the result of a $2.6B CMO merger. Brief
Biotech IT News
> Illumina likely to start charging for BaseSpace storage and processing in 2014. Story
> IMS: Big Pharma must turn to tech to cut $36B from their operating costs. Article
> Public enthusiastic--but wary--about sharing personal health data. Survey
> The rise of the Silicon Valley biocomputing startup. Piece
> Drop in federal funding threatens 22 jobs at the Broad Institute. Story
> Genome data nonprofit aims to raise $25,000 through crowdfunding. Brief